Exposure to topoisomerase II inhibitors is linked to the generation of leukemia involving translocations of the MLL gene, normally restricted to an 8.3 kbp tract, the breakpoint cluster region (BCR). Using an in vitro assay, apoptotic activators, including radiation and anti-CD95 antibody, trigger site-specific cleavage adjacent to exon 12 within the MLL BCR and promote translocation of the MLL gene in cells that can survive. To explore the mechanism of cleavage and rearrangement in more detail, the entire MLL BCR was placed into the pREP4 episomal vector and transfected into human lymphoblastoid TK6 cells. Episomes containing either the MLL BCR, or deletion constructs of 367 bp or larger, were cleaved at the same position as genomic MLL after exposure to apoptotic stimuli. Further analysis of sequence motifs surrounding the cleaved region of MLL showed the presence of both a predicted nuclear matrix attachment sequence and a potential strong binding site for topoisomerase II, flanking the site of cleavage. Inactivation of topoisomerase II by the catalytic inhibitor merbarone did not inhibit MLL cleavage, suggesting that the initial cleavage step for MLL rearrangement is not mediated by topoisomerase II.
Introduction
The generation of treatment-related leukemia's (tALL, tAML) is a risk linked to the cytotoxic agents used to treat a primary tumor. Such leukemia's are often associated with translocationmediated generation of fusion genes that are strongly implicated in the development of the disease. Translocations involving the MLL gene, located at 11q23, are observed with a wide range of partners in approximately 5% of patients with AML and 10% of patient's with ALL. 1, 2 In children under 1 year of age the incidence of MLL translocations in these diseases may reach 80%. 3 Of particular interest, specific translocations within MLL are observed in individuals exposed to topoisomerase II targeting drugs, such as etoposide, a potent apoptosis-inducing agent. 4, 5 Between 2 and 12% of all patients exposed to the epipodophyllotoxin class of topoisomerase II inhibitors will develop AML. 6 Most translocations within MLL occur in an 8.3 kb segment, operationally defined by BamHI restriction sites, known as the breakpoint cluster region (BCR). In particular, therapy-related breakpoints appear clustered towards the telomeric region of the BCR, a region that colocalizes with a DNase I hypersensitivity site and is also a target for site-specific cleavage induced by apoptotic agents. [7] [8] [9] We have demonstrated before that cells exposed to triggers of the apoptotic program may initiate MLL cleavage and subsequent translocation, within cells that have the potential to divide. 10 In addition, direct analysis has shown that the cleavage event is linked to the release of high molecular weight (B50 kbp) DNA fragments, an early event in apoptosis execution. 10 High molecular weight DNA fragmentation is a separable event from oligonucleosomal fragmentation (laddering), may be reversible, at least at an early time after exposure to apoptotic triggers and has been proposed to involve topoisomerase II activity. [11] [12] [13] Thus these observations link topoisomerase II activity to both a class of therapyrelated leukemia and the earliest chromatin modifications seen in apoptosis.
At least two tenable explanations have been proposed to explain the association between exposure to topoisomerase II inhibitors and the genesis of MLL linked translocations. In the 'topoisomerase II mediation' model, the association between MLL translocations and drugs that interfere with topoisomerase II function have led to the proposal that the enzyme is directly involved in generating the translocations. 4, 6 Despite the clear clinical association with exposure to drugs that interfere with topoisomerase II, scientific support for this mechanistic viewpoint is equivocal. In one in vitro study by Sim and Liu, a search was made for Topoisomerase II bound to the MLL breakpoint after exposure to the topoisomerase II inhibitor VP-16, a predicted consequence of topoisomerase II-mediated cleavage, but none were found.
14 Substantial data have been generated, however, showing a correlation between the site of in vitro topoisomerase II cleavage and the location of breakpoint fusion junctions. [15] [16] [17] An alternative mechanism that has been discussed, perhaps best termed the 'apoptotic nuclease' model, proposes that it is the activation of an apoptotic nuclease that initiates cleavage within MLL. 8, 10 Here, using an in vitro system, translocations could be generated by exposure to activators of apoptosis with no known link to topoisomerase II. 8, 14 This system also raises complex questions in terms of the requirement for such cells to avoid apoptotic execution and the implicit bias, as seen in the clinic, for the involvement of primarily those apoptotic activators that target topoisomerase II. Here, we present data that address the mechanism of MLL translocation induction and propose that the involvement of topoisomerase II is separate from its ability to mediate DNA cleavage.
Materials and methods

Cell lines
The human lymphoblastoid cell line TK6 was used for studies on MLL cleavage and episomal transfection. It is immortalized but not transformed and is highly sensitive to apoptosis induction. In addition, the MCF-7 cell line derived from a human breast tumor was used as this line lacks caspase-3, a component of the terminal effector pathway of apoptosis.
Detection of MLL cleavage by ligation-mediated PCR
This technique utilizes seminested PCR coupled with the specificity of ligation-mediated PCR to identify the location of DNA fragmentation events. DNA lesions introduced by apoptotic nucleases produce double-strand DNA breaks, allowing the ligation of a blunt-end linker molecule to the break-site. With the sequence of the linker molecule and approximate cleavage site known, it is possible to design primers to the region adjacent to the break-site, supporting a PCR reaction between the target and linker sequences. We have reported the technique in detail before. 10, 18 An estimate of the PCR product size by gel electrophoresis allows the site of cleavage to be deduced with good precision (710 bp). LM-PCR has been used by others to amplify DNA adjacent to internucleosomal breaks induced during apoptosis and breaks introduced during VDJ recombination. 19, 20 For these experiments, apoptosis was induced with ionizing radiation (Cs-137), and/or the topoisomerase II catalytic inhibitor, merbarone.
MLL seminested primers Figure 1 ). Execution of seminested ligation-mediated PCR on DNA extracted from cells exposed to apoptotic stimuli using 12.3F in round 1, followed by 12.2F in round 2 in conjunction with the linker 25 sequence above (2) now used as a primer, generates a 290 bp PCR product which, by reference to the primer location, places the predominant apoptotic cut site at B6768 bp within the MLL 8.3 kbp fragment.
Episomal-specific primer
This primer binds within the multicloning site of pREP4 adjacent to the site of MLL BCR insertion (vector sequence location 515-537 bp) such that, in conjunction with a primer to the adapter (Linker 25, #2 above) generates a product of approximately 1.5 kbp using pREP4 containing the complete 8.3 kbp MLL BCR insert.
Adapter preparation/ligation
For LM-PCR, 500 pmol of the two homologous adapter/linker oligonucleotides (#1, #2) are annealed together in 75 mM TrisHCl, pH 8.8, at a gradually decreasing temperature gradient, 951C for 5 min, 701C for 1 s and then the temperature lowered from 70 to 251C over 60 min. After incubation at 251C for 60 min, the temperature was lowered from 25 to 41C over a further 60 min. The now double-stranded adapter was then ligated to isolated genomic DNA using T4 DNA ligase by adding 1.0 mg of genomic DNA to 100 pmol (1.0 ml) of double-strand linker, 6 ml of 10 Â T4 DNA ligase buffer, 1.0 ml (3 U) of T4 DNA ligase and sfH 2 O added to a final volume of 60 ml. Prior to LM-PCR, the reaction mix is heated to 721C to dissociate the 11-mer oligomer, leaving a 5 0 , 25-mer overhang.
LM-PCR amplification
During PCR, Taq polymerase elongates the end of the staggered 25-mer to create the homologous strand producing a doublestranded 25-mer linker molecule ligated to all available DNA breaks, including the break of interest. PCR amplification is then conducted using the linker-ligated DNA as a template and the 25-mer oligonucleotide (#2) as one primer in conjunction with two additional MLL-specific primers (#3, #4) for the seminested reaction (sequences shown above). The first round reaction was carried out using Linker 25 primer plus 12.2F primer as follows 
Cleavage of MLL as an episomal fragment
For some experiments, the 8.3 kbp MLL BCR, or fragments derived from it by PCR amplification of 0.72 and 0.37 kbp that contain the apoptotic cleavage site as determined above were placed within the pREP4 (Invitrogen, Carlsbad, CA, USA) episome using standard techniques ( Figure 3 ). The smaller fragments were both constructed to include an adjacent topoisomerase II consensus sequence, approximately 100 bp 3 0 to the cut site. 16 In addition, the 8.3 and 0.72 kbp fragments contained an ATC tract, a sequence that has been associated with the ability to form nuclear matrix attachments through its capacity to become base unpaired. 22 After purification, 1 mg of each episome was transfected into target cells using DMRIE-C transfection reagent according to the manufacturer's protocol 0 region represents experimentally determined matrix attachment site. 16 Arrow shows approximate location of cleavage by enzymes of the apoptotic system as shown previously. 10 (Invitrogen, CA, USA). Subsequent analysis of cells exposed to apoptotic triggers used both episomal-specific (#2, and #5) primers and genomic MLL-specific primers (#2, #3 and #4) for LM-PCR as described above.
Detection of topoisomerase II activity
MCF-7 cells in exponential growth were either treated with 200 mM merbarone or buffer alone for a 30-min preincubation, followed by either no treatment or exposure to 8 Gy 137 Cs irradiation. Thereafter, protein was extracted from cells at increasing times and assayed for topoisomerase II activity by kinetoplast relaxation, according to the manufacturer's protocol (Topogen, Columbus, OH, USA). Using this system, functional topoisomerase II is determined by its ability to untangle kinetoplast DNA, which is then able to migrate through a gel during electrophoresis.
Detection of topoisomerase IIa protein
Nuclear cell lysates were collected from MCF-7 cells treated with 200 mM merbarone and equal amounts of lysate separated by electrophoresis on a 6% SDS-polyacrylamide gel. After transfer to nitrocellulose (Pall Corporation, East Hills, NY, USA) membranes were immunoblotted with either anti-topoisomerase IIa (Abcam Inc., Cambridge, MA, USA) or anti-p70 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) as a loading control. Membranes were subsequently incubated with secondary antibody coupled to horseradish peroxidase (Pierce Biotechnology Inc., Rockford, IL, USA), developed using SuperSignal West Dura Substrate (Pierce Biotechnology) according to manufacturer's instructions, and exposed on ECL Hyperfilm (Amersham, Piscataway, NJ, USA).
Results
MLL cleavage
Activation of the apoptotic program in TK6 cells by ionizing irradiation or exposure to anti-CD95 antibody leads to a sitespecific break within intron 11 of MLL, we have reported before that this corresponds to nucleotide position 6768 þ 10 bp within the 8.3 kbp MLL BCR, as determined by inspection of the amplicon size generated using LM-PCR with reference to the MLL primer binding sites (Materials and methods). In this scheme, all nucleotide locations refer to the 8.3 kbp breakpoint region numbered from 1 to 8332, using the notation of Gu et al 21 for the MLL BCR. In order to analyze the mechanism driving the cleavage observed, a range of episomal constructs were prepared that contained either the complete MLL BCR (8.3 kbp) or smaller fragments of 0.72 or 0.36 kbp that included the apoptotic cleavage site (Figure 1 ). These were transfected into TK6 cells using DMRIE-C transfection reagent (Invitrogen, Carlsbad, CA, USA). After 24 h the cells were challenged with 0.5 mg/ml anti-CD95 antibody for 4 h prior to LM-PCR analysis of MLL breaks. Using an episome containing the entire 8.3 kbp MLL BCR, LM-PCR was executed using a primer to the episomal backbone (#5 above) in conjunction with the linker primer (Linker 25). This allows analysis of breaks within the episome to be determined independently of those introduced into genomic DNA, as only vector and linker primers are used (Figure 2a) . As seen in Figure 2b (upper), a product of B1.5 kbp is observed using this primer system, which is consistent with a break in episomal MLL at the same or similar location as observed within genomic MLL. 8 Signal intensity of the amplicon fades as the amount of transfection agent is reduced. Fragmentation within genomic MLL is also observed in Figure 2b (lower) using LM-PCR primers to MLL and linker producing a 290 bp product as reported before. 8, 10 Here, the fragmentation is derived from both episomal MLL and genomic MLL fragmentation and is more intense than that observed in cells transfected with an empty vector, Figure 2c (lower) , where the LM-PCR signal is only derived from genomic MLL cleavage. The comparable sizes of the MLL-specific LM-PCR products in both Figure 2b and c (lower) provides independent evidence that episomal and genomic MLL are cleaved at the same, or similar, location. As is clear from Figure 2c (upper), vectors lacking the MLL insert were not cleaved and were thus not a substrate for LM-PCR analysis.
To gain insight into the mechanism of cleavage, episomes containing smaller fragments of the MLL BCR were also analyzed in a similar manner. As seen in Figure 3 , two episomal systems that contained 367 or 780 bp fragments of the MLL BCR were cleaved when transfected into TK6 cells, exposed to anti-CD95 antibody and analyzed by vector-specific PCR. Both episomes contained the apoptotic cleavage target site and a strong topoisomerase II consensus sequence approximately 100 bp distal to the cleavage site. 16 The smaller fragment lacked a predicted (guanine deficient) nuclear matrix attachment site of approximately 150 bp -however, this did not appear to affect cleavage. 22 Cleavage of either episome generated PCR products of approximately 500 bp, the predicted size if cleaved at the same location as either the 8.3 kbp BCR episomal fragment, or genomic MLL. Similar sized products will be produced for each episomal construct as the PCR reaction between the linker and the episomal backbone does not include the predicted nuclear matrix attachment sequence within the 780 bp episome. Nevertheless, the size of the LM-PCR episomal products as seen on the DNA gel was broader and less precise, suggesting cleavage occurred over a wider region of MLL. 
Nuclease(s) involved in MLL cleavage
At least two nuclease-dependent processes have been associated with chromatin attack in cells exposed to apoptotic triggers. Extensive DNA fragmentation, known as DNA laddering, is a caspase-3-dependent event that is mediated via activation of a specific nuclease, caspase activated deoxyribonuclease (CAD). 23 Separate from CAD-mediated laddering, an earlier and potentially unrelated nuclease-mediated cleavage occurs leading to the generation of high molecular weight fragmentation that involves apoptosis-inducing factor (AIF) and endonuclease G. 24 We have shown before that MLL scission is linked to early, high molecular weight cleavage as the MLL cleavage site can be detected at the termini of large DNA fragments released during apoptosis. 10 It was considered important to confirm this initial association, as it may provide a point of discrimination between cells accessing internucleosomal laddering, that are unlikely to survive, and those receiving far less frequent cleavage events, which may be reversible through effective repair. 12 To determine the effects of CAD elimination, we utilized the MCF-7 cell system that lacks caspase-3 function and has low or absent CAD activation or DNA laddering. 25 Triggering apoptosis by exposure to 8 Gy of ionizing radiation and analyzing cells by LM-PCR for MLL-specific, genomic, cleavage using the linker primer #2 and MLL-specific primers #3 and #4 generated the same (290 bp) fragment as seen after exposure of TK6 cells to apoptotic triggers (Figure 4a ). The size of the PCR amplicon and location of the MLL primers used places the site of cleavage at the same location as observed before in TK6 cells. 8, 10 The involvement of the apoptotic program was confirmed by prior exposure to 10 mM zVAD.fmk, a broad-spectrum caspase inhibitor, in this case no cleavage was seen. These data indicate that cleavage of MLL is associated with early, rare, chromatin fragmentation via a caspase-3 independent process.
Role of topoisomerase II in initial cleavage of MLL
As discussed in the Introduction, there is a strong and as yet not fully explained relationship between exposures of individuals to topoisomerase II inhibitors, in particular the epipodophyllotoxins, and the generation of acute leukemia's containing an MLL translocation. The epipodophyllotoxins such as VP-16 induce DNA breaks by stabilizing the cleavable complex between DNA and topoisomerase II. Target sites, more properly termed consensus sequences, for topoisomerase II binding are found at multiple locations within the MLL BCR, including in proximity to the apoptotic cleavage site within MLL. 16 Also, in vitro assays designed to detect topoisomerase II-mediated cleavage have been documented at the same locations involved in MLL breakpoint junctions; however, it has been difficult to design an unambiguous test of the role of topoisomerase II in generating translocations. 15 In the case of MLL, a specific target site for cleavage is known in response to apoptotic triggers, and documented above; however, translocation breakpoints in clinical material are found throughout the MLL BCR, making a direct assignment of mechanism from breakpoint position alone extremely difficult. To address the role of topoisomerase II in mediating the initial DNA strand break, MCF-7 cells were exposed to the catalytic inhibitor merbarone and then irradiated with 8 Gy. This drug inactivates topoisomerase II prior to cleavable complex formation thus no drug/topoisomerase II-mediated DNA breaks are introduced. As shown in Figure 4c using a decatenation assay based on protein extracts taken from merbarone-treated cells, exposure to the drug rapidly inactivated topoisomerase II function, leading to no detectable enzyme activity over the duration of the experiment. This effect may be due to either direct enzyme inactivation by the drug and/or increased degradation or modification of the topoisomerase II. To address this question a Western blot analysis of topoisomerase IIa was performed that showed a gradual decline in the level of detectable topoisomerase IIa over the course of 8 Black triangles are breakpoint junction sites within MLL, part of MLL-AF9 fusions, observed in a recently reported set of tAML patients at 6589, 6592, 6593, 6593 and 6594. 26 Top horizontal bar is a region of potential base unpairing linked with nuclear matrix attachment. White box is MLL exon 12 that contains a topoisomerase II consensus sequence (black box). Dotted lines represent pREP4 backbone; primer location is for the vector-specific reaction, shown as primer (4) in the text and used in Figure 2 . (b) Both episomal fragments (I and II) contain the topoisomerase II consensus sequence and are cleaved when transfected (using 0-12 mg/ml DMRIE) into TK6 cells that are subsequently exposed to anti-CD-95 antibody. MLL BCR notation of Gu et al. the experiment (Figure 4d) . Thus, it is apparent that merbarone induces rapid functional loss of topoisomerase II activity, leading to an increase in its degradation, without gross alteration in the level of topoisomerase IIa (see 0.5 h time point Figures 4c  and d) . Significantly, however, merbarone-treated cells were still cleaved at the MLL target site, with or without prior exposure to irradiation, the merbarone itself providing the apoptotic stimulus without irradiation (Figure 4b ). This implies that the DNA cleavage and strand passing function of topoisomerase II are not essential for the initial cleavage step within MLL.
Discussion
The incidence of secondary leukemia's after primary therapy is a continuing concern. The clear association of these diseases with prior treatment, primarily cytotoxic drugs or irradiation, is consistent with DNA damage from such clastogens being the causative agent in generating leukemogenic translocations and/ or deletions. More detailed analysis of these data has shown that drugs targeting topoisomerase II, particularly the epipodophyllotoxins, are strongly linked to the initiation of AML through translocations of the MLL gene. [4] [5] [6] Such translocations occur primarily within an 8.3 kbp region of MLL DNA, the BCR, adjacent to exon 12, operationally defined by two BamHI restriction sites. Within this region, AML's linked to prior treatment have been shown to contain MLL breakpoints that are clustered towards the telomeric end of the BCR, the same region associated with specific DNA cleavage induced by proapoptotic treatment. 16 These data are broadly compatible with either a topoisomerase II or apoptotic nuclease-mediated mechanism as discussed in the Introduction. Perhaps surprisingly, it has not been possible to simply discriminate between these two possibilities by inspection of the breakpoint junctions observed in clinical material. Both topoisomerase II and apoptotic nuclease mediated models predict the initial cleavage event to occur at specific sites, and examples of this have been described. 8, 15 However, it is likely that the majority of breaks will undergo some processing prior to translocation -masking the precise site of initial cleavage. In one recent study, Whitmarsh et al 15 have described a patient with an MLL-AF9 translocation where translocation had taken place between identical 5 0 -TATTA-3 0 sequences within MLL and AF9, a process that did not require further processing of the break sites. In the case of MLL, the breakpoint was found to be between 6588 and 6593, complementary in vitro studies showed specific cleavage at this and multiple other locations using purified topoisomerase II, drug inhibitors and MLL target DNA. 15, 21 The location identified in MLL is of clear clinical interest as a potential translocation hotspot as others have found breakpoints in therapy-related AML that contained MLL-AF9 translocations at the same position. 26 ( Figure 3) . Interestingly, using a model cellular system to create MLL translocations in vitro, we have shown that apoptotic triggers, including ionizing radiation and anti-CD95 antibody, were able to induce translocations in MLL that were tightly clustered around the same location as observed clinically (Betti et al 8 and Figure 3 ). Using LM-PCR generated data as reported before, the site of apoptotic cleavage was determined to be at 6768710 bp within intron 11 of MLL, approximately 200 bp distal to the site of the experimental translocation cluster. 8, 10 This is consistent with processing of the DNA break prior to translocation generation. Clinical observations support such a possibility in that examination of MLL-AF4 and MLL-AF9 translocations from patients with acute leukemia, translocations were both frequently observed and exhibited loss of sequence at the break sites of a comparable size, B100 bp. 26, 27 In the studies reported here, neither inducing agent (radiation or anti-CD95 (Fas) antibody) have any known direct interaction with topoisomerase II. The remarkable similarity in the breakpoint junctions induced experimentally, and those observed in clinical material, implies that a common mechanism may be involved. The primary link that joins both the clinical and experimental observations together may be the target DNA sequence itself within MLL. For this reason, the MLL target region was investigated further.
In order to understand the mechanism driving apoptotic nuclease cleavage and subsequent translocation at this site, we created a series of episomes containing the MLL BCR. This follows a previous study by Stanulla et al 28 showing the feasibility of such an approach. This strategy will potentially enable documentation of the essential elements required for effective nuclease attack at this location. It is clear that genomic MLL is a target of site-specific cleavage at the intron 11/exon 12 border in a variety of human cells. 7, 8, 10 As shown in Figures 2  and 3 , both the entire 8.3 kbp MLL BCR and smaller fragments of 367 and 780 bp were subject to cleavage when placed as episomes in cells that were subsequently triggered to undergo apoptosis. Of note, all episomal inserts that supported cleavage contained both a strong topoisomerase II consensus binding site (at 6864-6847 as noted in Broeker et al 16 ) and the target for apoptotic cleavage at 6768 bp (see Figure 3) . In addition, the episome containing the larger fragment also includes a tract of guanine-deficient DNA that has been experimentally linked to the ability of such DNA to bind to the nuclear matrix. 22 We and others have noted an association between both DNA cleavage and translocation potential associated with such sites. 9, 10 No significant effect on DNA cleavage was observed linked to either the presence or absence of this tract. Further studies will be required to establish whether this or other experimentally defined nuclear matrix attachment sites have a role in either DNA cleavage and/or translocation potential. The presence of a topoisomerase II consensus sequence does not necessarily confirm that cleavage and/or binding of this enzyme will take place at that location. However, analysis of all the topoisomerase II consensus binding sites in the MLL BCR shows that the strongest predicted site (10/10 required bases) is within 100 bp of the cleavage target. 16, 29 These data indicated that the motifs likely responsible for targeted cleavage are contained within a relatively small tract of MLL-associated DNA. The fact that all episomal constructs contained a topoisomerase II consensus site, the demonstrated ability of topoisomerase II to initiate cleavage within this region and the involvement of topoisomerase II inhibitors in the etiology of secondary leukemia's stimulated a further investigation of this enzyme in mediating the initial cleavage event.
For these experiments, the caspase-3 null MCF-7 cell line was used, exposed to 8 Gy and cleavage within MLL determined by LM-PCR. As seen in Figure 4a , site-specific cleavage was observed in an apoptosis-dependent manner, the 290 bp LM-PCR amplicon signal being absent in the presence of the pancaspase inhibitor, zVAD.fmk. These data confirmed that this cleavage event was not associated with early, caspase-3-dependent internucleosomal laddering. As a first step, topoisomerase II function was suppressed by exposure of this cell line to merbarone, a catalytic inhibitor of topoisomerase II (Figure 4b ). Unlike the epipodophyllotoxin class of inhibitors such as VP16 (etoposide), merbarone inactivates the enzyme prior to formation of the cleavable complex, thus DNA is not broken as a consequence of drug interference with topoisomerase II activity. 30 As shown in Figure 4c , exposure to 200 mM of the drug immediately suppressed topoisomerase II function over a 2-day period. Over the same time period, the level of nuclear extractable topoisomerase II gradually fell, probably a result of increased drug-induced degradation. Thus using merbarone alone, or merbarone plus 8 Gy, cleavage at the apoptotic target site was still observed in cells that had topoisomerase II function suppressed. Both the drug itself and irradiation are proapoptotic agents; in neither case did inactivation of topoisomerase II limit cleavage.
It is concluded from these data that topoisomerase II is unlikely to be the active agent mediating site-specific cleavage subsequent to apoptotic stimulation. These data are in accord with our previous study where both cleavage and translocations within this region of MLL may be triggered by exposure to anti-CD95 antibody alone. 8 This, in conjunction with the remarkable concordance of recent clinical data on the location of breakpoint junctions in a series of infant AML's with those induced experimentally using agents that do not target topoisomerase II, suggest that topoisomerase II may act in a secondary, but clearly important role as a facilitator of translocations. 8, 26 One possibility may be that modifying the function of topoisomerase II by specific chemotherapeutics, such as etoposide, creates alterations in local supercoil tension and/or topology. 31 Interference with topoisomerase II function in this manner may enhance accessibility of the DNA to apoptotic nucleases, and/or affect accurate repair of the now distorted DNA. These data emphasize the complexity underlying the generation of clinically significant translocations involving MLL that are therefore unlikely to be linked to a single causative event.
